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Introduction: Both autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED) and the rare thymoma patients with chronicmucocutaneous
candidiasis (CMC) have neutralizing autoantibodies to Th17 cytokines and
significant defects in production of IL-22 and IL-17F by their T cells. The cause of
these defects is unknown. We hypothesized that they might result from
autoimmunity against upstream cytokines normally responsible for generating and
maintaining Th17 cells.
Methods: Luciferase immunoprecipitation (LIPS) was used to screen for
autoantibodies to IL-6, IL-1b, TGF-b3, IL-21, and IL-23 in patients with APECED
or thymoma. We used Western blotting to assess the conformation-dependence
of the IL-6 autoantibodies and flow cytometric analysis of intracellular phospho-
STAT3 induction to assess IL-6-neutralizing capacity in IgGs isolated from
patient and control sera. We also used Luminex xMAP to measure serum cytokine
levels.
Results: We found autoantibodies binding to conformational epitopes of IL-6 in
19.5% of 41 patients with APECED and 12.5% of 104 with thymoma—especially in
those with long disease durations. The autoantibodies were predominantly of IgG1
subclass and failed to neutralize IL-6 activity. Notably, serum levels of the IL-6 and
IL-17A cytokines were higher in anti-IL-6 seropositive than—negative APECED
patients or healthy controls. We also detected autoantibody binding to IL-23 in
27.9% of thymoma patients, resulting from cross-recognition through the p40
subunit it shares with IL-12.
Conclusions: IL-6 and IL-17A elevation in these seropositive patients suggests
that antibody-binding may protect IL-6 from degradation and prolong its half-life
in vivo.
Introduction
Autoantibodies that block the biological functions of
cytokines can predispose to certain infections. For instance,
neutralizing antibodies against IFN-g lead to disseminated
mycobacterial infections [1, 2], high-avidity antibodies
against IL-6 cause serious staphylococcal infections [3], anti-
granulocyte macrophage colony–stimulating factor autoan-
tibodies have been linked to cryptococcal meningitis [4], and
anti-IL-12p70 autoantibodies to recurrent Burkholderia
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gladioli suppurative lymphadenitis [5]. Moreover, autoanti-
bodies neutralizing the T helper (Th)17 cytokines interleu-
kin (IL)-22, IL-17F, and IL-17A are associated with chronic
mucocutaneous candidiasis (CMC) in most patients with
the rare monogenic disease autoimmune polyendocrinop-
athy-candidiasis-ectodermal dystrophy (APECED) and also
in a few patients with thymic epithelial cell neoplasia [6, 7].
The obvious connections between these syndromes are
aberrations in thymic epithelium [6, 8, 9], the major cell type
to express theAIRE gene that is mutated in APECED [10, 11]
and often under-expressed in the thymoma epithelial
cells [12].
Whether the Th17 cytokine-neutralizing autoantibodies
alone are sufficient to precipitate CMC is still disputable. In
addition to autoantibodies, APECED and thymoma patients
with CMC show severely impaired IL-22 and IL-17F
production [6, 13–15]. Interestingly, IL-17A secretion by
APECED T cells can range from almost absent in some
patients to supra-normal in some others [6, 14, 15]. This led
us to hypothesize that neutralizing autoantibodies to Th17-
driving cytokines (IL-1b, IL-6, IL-21, IL-23, and/or TGF-b)
[16–18] might be involved in shaping or stunting Th17
responses.
The aim of the present study was to measure autoanti-
bodies to cytokines important for Th17 cell generation or
maintenance with LIPS assays, determine their IgG isotypes,
neutralizing capacity, and requirements for natural confor-
mational epitopes.
Materials and Methods
Patients and controls
We studied 41 Finnish and Slovenian patients with APECED
(Supporting information, Table S1, [6]), 104 with thymo-
mas, 99 of them with myasthenia gravis (MG) plus
acetylcholine receptor antibodies (Supporting information,
Table S2; [6, 19, 20]) and healthy controls (n¼ 56; 51 15.9
years old). The APECED diagnosis was confirmed by
mutation analysis of AIRE genes and by the presence of
autoantibodies to IFN-v and IFN-a2. About 50% of the
thymoma patients were first sampled pre-treatment; though
times and doses varied, most eventually needed corticoste-
roids (alternate days) azathioprine for their MG. Where
possible, sera were stored in aliquots and only thawed
immediately before use. The study was conducted in
accordance with the Helsinki Declaration, with informed
consent and local Ethics Committee approval.
Autoantibody detection with LIPS
LIPS was carried out as previously reported [21, 22]. IL-6,
IFN-v, IL-1b, IL-21, IL-23A (p19), IL-12A (p35), and
IL-12B (p40) or TGF-b3 sequences (without signal peptide)
were cloned into modified pPK-CMV-F4 fusion vector
(PromoCell GmbH, Heidelberg; Germany) downstream of
naturally secreted Gaussia luciferase (Gluc) that was
substituted in the plasmid for Firefly luciferase. HEK293
cells were transfected with the cloned constructs, and tissue
culture media containing Gluc-fusion proteins were col-
lected after 48 h and stored at 208C. Serum samples were
incubated with IL-6, IFN-v, IL-1b, IL-21, IL-23, or TGF-b3
fusion protein solutions (2 106 luminescence units)
overnight at þ48C. Next day, Protein G agarose beads
(25ml of 4% suspension, Exalpha Biologicals, MA) were
added and incubated at room temperature for 1 h in 96-well
microfilter plates (Merck Millipore, Billerica, MA) to
capture antibodies and immune complexes to the beads.
After washing to remove unbound fusion proteins, luciferase
substrate was added (coelenterazine GAR-2B, Targeting
Systems, El Cajon, CA), and luminescence intensity (LU)
measured in VICTOR X Multilabel Plate Readers (Perki-
nElmer Life Sciences,Waltham,MA). Results were expressed
as relative units ðRUÞRU ¼ LU sampleaverage LU of healthy control samples.
The positive/negative discrimination level was set to the
mean plus 3 standard deviations of the healthy control
samples.
Patients with the highest binding values were selected for
IL-6 and IL-23 blocking experiments. Briefly, the serum
samples were pre-incubated with 40mg/ml of recombinant
human (rh) IL-6, (PeproTech EC Ltd, London, UK) or
rhIFN-g (Miltenyi Biotec, Bergisch Gladbach, Germany). To
test for IL-23- blocking, the thymoma serum samples were
pre-incubated with 40mg/ml of rhIL-23 (PeproTech EC Ltd,
London, UK), rhIL-12 (PeproTech EC Ltd, London, UK), or
rhIL-6 (PeproTech EC Ltd, London, UK). The samples were
rotated for 2 h at room temperature and centrifuged for
15min at 16,000g and supernatants were transferred into
new Eppendorf tubes before performing LIPS assay as above.
To render the assay IgG subclass-specific, agarose beads
coupled with streptavidin (25ml of 4% solution, Life
Technologies, Carlsbad, CA) were coated with 10ml of
biotin-conjugated human subclass-specific antibodies
(1:100 dilution, anti-IgG1, anti-IgG2, anti-IgG4, from BD
Pharmingen, anti-IgG3 from Life Technologies, Carlsbad,
CA) for 1 h in microfilter plates (Merck Millipore), to
capture any subclass-specific immune complexes formed
during the standard overnight pre-incubation, before
washing and readout as above. The results were expressed
as RU.
Purification of immunoglobulins
Immunoglobulins were isolated from six APECED patients’
and six control sera. Total IgG fractions were separated with
fast protein liquid chromatography using Protein G
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Sepharose 4 Fast Flow (GE Healthcare, Biosciences, Little
Chalfont, UK), eluted at pH 2.5, concentrated, and buffer-
exchanged with phosphate-buffered saline (PBS) with
iConTM concentrator 7ml/20 K tubes (Pierce Biotechnology,
Inc., Rockford, IL). Protein concentrations were determined
with Nanodrop 2000c (Thermo Scientific, Waltham, MA).
Assay for neutralization of IL-6 activity
We tested the APECED and control IgG fractions according
to BD PhosflowTM Protocol for Human Whole Blood
Samples (mild or harsh alcohol method). About 25ml
(0.6mg/ml) of purified IgG was incubated with 25ml (5 ng/
ml) of recombinant human IL-6 (Biolegend, San Diego, CA)
at 378C for 1 h before addition to 50ml of fresh heparinized
whole blood and incubation for a further 15min in a 378C
water bath, and fixation for 10min with 2ml of pre-warmed
Lyse/Fix Buffer (BD Bioscience, Franklin Lakes, NJ). The
cells were then permeabilized with pre-chilled Perm Buffer
III for 30min on ice. Mouse anti-human STAT3 (pY701)-PE
antibody (BD Bioscience) was used to quantify the biological
effect of IL-6 with LSR Fortessa (BD Bioscience). Results
were analyzed with FCS Express 5 Plus (De Novo Software,
Glendale, CA).
Western blot
IFN-v and IL-6 luciferase fusion proteins were heated at
958C for 4min in reducing sample buffer [3% SDS, 10%
glycerol, 0.1M dithiothreitol, 0.02% bromophenol blue and
6.25mM Tris–HCl, pH 6.8], run in 12% SDS–PAGE and
blotted onto polyvinylidene difluoride filters. After blocking,
strips of the filter were incubated with patient or control sera
(1:100) or rabbit anti-luciferase antibody (1:1000 New
England Biolabs, Ipswich, MA) followed by secondary
antibodies (anti-human HRP 1:10,000 and goat anti-rabbit-
HRP 1:5000; Jackson ImmunoResearch, West Grove, PA,
USA, Inc.), and visualization by enhanced chemilumines-
cence using the manufacturer’s protocol (GE Healthcare,
Little Chalfont, UK).
Cytokine measurements
The Milliplex Magnetic Bead Panel (Millipore, Billerica,
MA) was used to quantify IL-6, IL-17A, IL-17F, and IL-22 in
APECED patient and control sera (stored continuously
at 208C) using the Luminex xMAP system (Luminex,
Austin, TX) according to the manufacturer’s protocol.
Briefly, beads coupled with monoclonal antibodies to
cytokines were sonicated, mixed, and diluted in bead
diluent. They were incubated overnight at 48C with serum
samples, or standards or two positive controls, in 96-well
filter plates, and then with detecting antibodies for 1 h,
before addition of streptavidin-PE and analysis on a
Luminex 200 instrument (Luminex) using Luminex xPO-
NENT software (version 3.1). Positive control values fell
within the expected range.
Statistical analysis
GraphPad Software (San Diego, CA) and one-way ANOVA
with Bonferroni’s Multiple Comparison test was used to
assess differences between studied groups.
Results
APECED and thymoma pat ients share
autoantibodies specific for IL-6 but anti-IL-23 is
present only in thymoma patients
Sera from patients with APECED or thymomas and healthy
controls were tested for autoantibodies against IL-6, IL-1b,
IL-21, IL-23 (p19þ p40), or TGF-b3 using LIPS assays that
preserve the natural cytokine conformations. We could not
detect any significant autoantibody binding to IL-1b, IL-21,
and TGF-b3 except for single borderline reactivities to IL-1b
and IL-21 (Fig. 1A–C). But we found autoantibodies to IL-6
in 8 of the 41 APECED (A1, A9, A18, A22, A27, A32, A34,
A36) patients’ sera (19.5%, Fig. 1D; Supporting information
Table S1); also in 13 (12.5%) of 104 thymoma patients (T1,
T14, T23, T24, T31, T32, T34, T37, T43, T48, T50, T53, T56),
though mostly at moderate levels (Fig. 1D; Supporting
information Table S2). Three of the anti-IL-6 positive
thymoma patients also had autoantibodies against IFN-a2a,
IL-17s, and/ or IL-22. Notably, two (patients T24 and T31)
showed remarkably high IL-17A- and IL-17F-binding and
had candidiasis (Supporting information Table S2); never-
theless, these antibodies cannot be a strong predisposing
factor, as two other patients with CMC and five with
intercurrent Candida infections tested negative against IL-6
(Table S2). Similarly, T37 had severe acne at age 25, but we
found high-level IL-6 antibodies only >10 years later. As
expected, other infections were common in the thymoma
patients, many of whomwere taking corticosteroids for their
MG, but, again, they did not clearly co-occur with the IL-6
antibodies (Table S2).
Notably, two of 56 (3.6%) control sera showed moderate
but consistent anti-IL-6 levels (Fig. 1D). Altogether, there
were too few anti-IL-6 positive APECED and thymoma
patients to justify correlations with other demographic or
clinical parameters or tumor histology.
Thymoma patients are known to have autoantibodies to
IL-12 [20, 23]; which we found here in 91 of 104 sera (90%;
Supporting information Table S2); in different cases, they
recognize its p40 subunit or only the p35/p40 heterodimer
(A. Meager unpublished). They also substantially inhibit
J. K€arner et al. Anti-IL-6 autoantibodies
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Th1-cell polarization [24]. Therefore, it was not surprising to
find autoantibodies to IL-23, as it shares the p40 subunit
with IL-12. Notably, they were evident only in patients with
thymoma but not in APECED. Indeed, p19þ p40 were
bound by 28 of the 92 IL-12 positive thymoma patient sera
(Fig. 1E, Table S2). However, none of them showed
reactivity against the IL-23-specific chain p19 alone
(Supporting information Fig. S1). These IL-23 autoanti-
bodies did not correlate with CMC in thymoma patients.
We next confirmed the specificity of the autoantibodies
detected. Pre-incubating positive APECED or thymoma
patients’ sera with recombinant human (rh) IL-6 completely
blocked subsequent binding to IL-6 in LIPS assays
(p< 0.01), whereas a control cytokine, rhIL-IFN-g, had
no such effect (p> 0.05; Fig. 2A). Further supporting the
p40-specific cross-reactivity between IL-12 and IL-23 noted
above, these cytokines both strongly blocked binding by the
anti-IL-23 antibodies (p< 0.0001 for each), with almost
equal potency (p> 0.05) (Fig. 2B).
Taken together, IL-6 was the only Th17-driving cytokine
that was recognized by autoantibodies in both APECED and
thymoma patients. Moreover, these autoantibodies did not
correlate with the presence or severity of CMC in either
disease group, in spite of their theoretical potential to
interfere with Th17 responses.
High-level anti-IL-6 autoantibodies are a late
feature
We tested the available serial samples from patients with
longer disease durations (Supporting information, Fig. S3).
In APECED, titers against both type I IFNs and Th17
Figure 1. Cytokines related to Th17 maintenance and differentiation were tested with LIPS analysis for autoantibodies in APECED (41), thymoma (104)
patients, and 56 healthy controls.
Figure 2. Binding speciﬁcities of IL-6 and anti-IL-23 antibodies in APECED and thymoma patients. (A and B) Blocking of APECED and thymoma patients’
serum antibodies by pre-incubation with recombinant human (rh) IL-6, rhIFN-g, rhIL-23, or rhIL-12; no, no pre-incubation; ns, not signiﬁcant; (C) IFN-v
and IL-6 LUC fusion proteins were denatured in SDS buffer, separated with PAGE and analyzed by Western blot using patient control sera or anti-
luciferase (LUC) antibody. A, APECEDl; T, thymoma.
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cytokines are nearly maximal at diagnosis [6, 25], and are
found before onset of CMC in informative cases and even in
infancy [6, 7]. Moreover, they tend to decline subsequently
(Supporting information, Fig. S3). Likewise, in seropositive
thymoma patients, IFN-a and/ or IL-12 antibodies are
mostly found at diagnosis, though their titers usually rise
sharply if the thymoma recurs, and may vary with changes in
doses of immuno-suppressive drugs [16].
In sharp contrast, the IL-6 autoantibodies—when
present—were low initially but apparently increased over
time in both patient groups, and were maximal in samples
taken decades after disease onset (Supporting information,
Fig. S3). In T53, they were negative at thymomectomy but
positive when a recurrence was found 15 years later (not
shown).
The IL-6 autoantibodies are mainly IgG1 and
recognize conformational epitope(s)
We next modified the LIPS assay to check the IgG
subclasses of the antibodies in the six strongest IL-6-
binding sera (Table 1, three patients with APECED and
three with thymoma). Reactivity was mainly in the IgG1,
except in T1, where it was found in all four subclasses
(Table 1).
We next used Western blotting to test for recognition of
conformation-independent epitopes by the strongest
APECED sera. Binding was not detected to denatured
IL-6: however, it was still strong against IFN-v (Fig. 2C),
which we used as a positive control, as autoantibodies are
known to recognize linear epitopes in type I interferons
too [21]. Moreover, even the strongest LIPS-positive sera
showed minimal binding to IL-6 by ELISA (Supporting
information, Fig. S2), confirming that native conforma-
tional epitopes in IL-6 are easily disturbed.
Autoantibodies fail to neutralize IL-6, but
correlate with higher IL-6 levels
To help to understand the biological significance of these
autoantibodies against IL-6, we next tested their capacity to
inhibit signaling from its receptor via phosphorylation of
STAT3, which acts downstream in this pathway. FACS
analysis clearly showed no inhibition by purified IgGs from
six APECED patients; indeed, mean signals were even
marginally higher than with the six control IgGs (3.927 vs.
3.584, p> 0.05; Fig. 3A). This is well in line with the rarity of
staphylococcal infections in APECED patients, and argues
strongly against our hypothesis that anti-IL-6 autoanti-
bodies are involved in the pathogenesis of CMC in APECED
patients.
Next, we studied the serum levels of IL-6 and of the Th17
cytokines IL-17A, IL-17F, and IL-22 in the available
unthawed APECED and healthy control serum aliquots.
IL-17F and IL-22 levels were below the detection limit in
most of these sera, but IL-6 and IL-17A levels were both
higher in the two anti-IL-6 positive patients than in the nine
negatives or the ten healthy controls (p< 0.001, Fig. 3B and
C). This finding suggests that IL-6-specific autoantibodies
could prolong the half-life of IL-6 in vivo and so indirectly
enhance IL-17A production by Th17 cells.
Discussion
In this study, we showed that among Th17-driving
cytokines, only IL-6 was recognized by autoantibodies in
some APECED and thymoma patients, and IL-23 in some
thymoma patients. Anti-IL-23 autoantibodies have been
previously reported in two patients: one with a thymoma
and the other with congenital immunodeficiency, using
protein microarray and microbead-based assays [26]. Both
of them were also anti-IL-12 positive—which strongly
implicates the p40 subunit (which these cytokines share) in
their cross-recognition. That is supported by the data shown
here—both the equally potent blocking of IL-23 LIPS signals
by recombinant IL-23 and IL-12 (Fig. 2B) and our failure to
detect any reactivity toward the p19 subunit of IL-23
(Supporting information Fig. S1). Moreover, these anti-
bodies clearly neutralize IL-12 in bioassays [20] and inhibit
Th1-cell polarization [24].
Like the autoantibodies against type I IFNs, Th17
cytokines and/or some organ-specific auto-antigens [8],
those against IL-6 were shared between APECED and
thymoma patients, but were found later in the disease course
and much less frequently. IL-6 is a pleiotropic cytokine that
signals through STAT3 and is evidently critical in protection
against staphylococcal and fungal infections. Indeed, an
autosomal dominant form of hyper-IgE syndrome that is
caused by STAT3mutations is characterized by susceptibility
Table 1. IL-6-speciﬁc IgG subclasses in APECED and thymoma patients.
IgG1 IgG2 IgG3 IgG4
APECED
A23 25 1 3 1
A28 1 1 29 1
A35 31 1 1 1
Thymoma
T1 2 3 2 3
T37 6 1 1 1
T48 27 1 1 1
The values are expressed as RU (fold changes over the average
luminescence of healthy control samples). Positive values are marked
bold. A, APECED patients; T, thymoma patients.
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to staphylococcal abscesses and CMC [27]. In addition, high
titer neutralizing autoantibodies to IL-6 have previously
been associated with chronic staphylococcal cellulitis and
subcutaneous abscesses in one patient [3]. However, studies
on large numbers of healthy blood donors have revealed
IL-6-binding reactivity in up to 9% of them and also in IgG
preparations, using either RIA or ELISA in earlier studies [28,
29]. 0.1% of the sera showed high binding levels and were
able to neutralize the biological function of IL-6 without any
sign of disease in the respective donors [28]. Disparately
from these previous studies, the IL-6 autoantibodies we
detected in our APECED and thymoma patients were
probably targeted to different—more conformation-
sensitive—epitopes: even adsorption to plastic abolished
the binding as well as unfolding in SDS buffer. Interestingly,
many of the anti-cytokine autoantibodies in APECED are
focused on conformational epitopes [21]; in IL-22, these are
mostly lost when it is adsorbed to plastic for ELISAs [6].
Tests carried out in solution, where its natural conformation
is preserved (neutralization, LIPS, bead-based assays), show
superior sensitivity [6, 7, 22, 30]. Autoantibodies to IL-12
and IL-23 seem to be less conformation-dependent: many
can be detected using protein arrays [26], ELISAs [20], or
even immunoblotting (A. Meager, unpublished data).
Furthermore, the autoantibodies binding to IL-6 in
APECED sera did not neutralize its function (Fig. 3A). So
it seems unlikely that they are involved in the pathogenesis of
CMC in APECED. Conversely, IL-6-specific autoantibodies
in systemic sclerosis have been suggested to stabilize IL-6 in
vivo as carriers, as its levels were higher in autoantibody
positive patients than innegatives, and IL-6 activitywas found
in the immune complexes [31]. Cytokine-stabilizing function
has also been reported for anti-IL-2 [32]. Antibodies are
currently thought in certain cases to increase the persistenceof
Figure 3. Testing for biological effects of IL-6 antibodies (A) intracellular phospho-STAT3 staining in cells incubated with medium alone (black), or plus
IL-6 (red) or plus IL-6 pre-incubated with either APECED patients’ IgG (blue) or controls’ IgG (green). Serum concentrations of IL-6 (B) and IL-17A (C) in
APECED patients with or without IL-6-speciﬁc autoantibodies and in age-matched healthy controls. APECED patients positive for anti-IL-17A
autoantibodies are indicated with red open diamonds.
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the cytokine in the circulation: IgG is taken up by neonatal Fc
receptors (FcRn) expressed on vascular endothelium and
myeloid cells. IgG is pinocytozed together with plasma and
binds to FcRn in late endosomes, and is recycled back to the
plasma still retaining its bound cytokine [33]. Indeed, certain
IL-2/anti-IL-2 complexes were degraded faster in FcRn-
deficient mice [34]. Notably, IgG1 has the highest affinity for
nFcR [35], and was the predominant subclass in all
informative samples. Whether such stabilization occurs in
our patients requires further testing. However, our data
indirectly suggest that the IL-6 autoantibodies can potentiate
Th17 development; the two informative anti-IL-6 positive
patients had the highest IL-17A levels in their sera (Fig. 3B and
C). They were both anti-IL-17A-negative, as were six of the
nine anti-IL-6-negative patients (Fig. 2C). Moreover, one of
the two present anti-IL-6 positive patients (A35) had the
highest percentage of IL-17A-producing T cells in our
previous study (Fig. 3C from Ref. [6]).
The reasons for autoimmunization against certain
cytokines are not known. Autoantibodies have been detected
in numerous diseases where the respective cytokine is
overproduced (e.g., type I IFNs in SLE and interferono-
pathies) [9, 20, 36]. In theory, they might modulate the
disease course [37, 38]. However, they rarely neutralize and
their titers are much lower than those in APECED and
thymoma patients [20, 30]. Such low-level IFN-a-binding
but non-neutralizing antibodies seemed to appear after
intercurrent infections in other patient groups [20]. We
suspect that the infrequent IL-6-binding antibody responses
noted here have analogous origins. That is supported by
their detection only several years after diagnosis, which
contrasts starkly with the same patients’ anti-IFN-a and
IL-22 antibodies, which are found much earlier and much
more frequently, and also show intriguing early and
persistent IgG4 biases [21].
Conclusions
In conclusion, we found autoantibodies binding IL-6 in
some long-duration APECED and thymoma patients, and
autoantibodies to IL-23 that cross-reacted with IL-12 in
thymoma patients. These IL-6 autoantibodies weremostly of
IgG1 isotype, bound to conformational epitopes, and did not
neutralize. Our data imply that they do not predispose to the
candidiasis in these two syndromes. Whether they instead
protect IL-6 from degradation and prolong its half-life in
plasma, potentially enhancing its biological functions in
vivo, warrants further testing.
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